Literature DB >> 9050108

Research in schizophrenia and the discontinuation of antipsychotic medications.

R J Wyatt1.   

Abstract

This article, and the accompanying one by Dr. Carpenter, discuss the benefits and risks associated with taking patients with schizophrenia off medications for research purposes. This article reviews the concept that at least some forms of schizophrenia are progressive. Evidence for this view is provided by studies examining the impact of early intervention with antipsychotic medications on the long-term morbidity of schizophrenia, as well as the few studies examining the long-term risks of discontinuing antipsychotic medications in patients with schizophrenia. While there is evidence that early intervention improves the long-term course of the illness, it is not known whether withdrawal of antipsychotic medications increases long-term morbidity. This is an area where further information is needed for clinical practice and research.

Entities:  

Keywords:  Biomedical and Behavioral Research; Mental Health Therapies

Mesh:

Substances:

Year:  1997        PMID: 9050108     DOI: 10.1093/schbul/23.1.3

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  10 in total

1.  Traditional ethics and new sensitivities.

Authors:  William T Carpenter
Journal:  Schizophr Bull       Date:  2005-11-17       Impact factor: 9.306

2.  The revolving door of mental, neurological, and substance use disorders re-hospitalization in rural KwaZulu-Natal Province, South Africa.

Authors:  Andrew Tomita; Yoshan Moodley
Journal:  Afr Health Sci       Date:  2016-09       Impact factor: 0.927

Review 3.  Medication-free research in early episode schizophrenia: evidence of long-term harm?

Authors:  John R Bola
Journal:  Schizophr Bull       Date:  2005-10-27       Impact factor: 9.306

4.  Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP).

Authors:  José María Pelayo-Terán; Virginia Gajardo Gajardo Galán; Víctor de la Ortiz-García de la Foz; Obdulia Martínez-García; Rafael Tabarés-Seisdedos; Benedicto Crespo-Facorro; Rosa Ayesa-Arriola
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-10-28       Impact factor: 5.270

5.  The long-term effects of placebo in patients with chronic schizophrenia.

Authors:  R J Wyatt; I D Henter; J J Bartko
Journal:  Biol Psychiatry       Date:  1999-10-15       Impact factor: 13.382

Review 6.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  The German Research Network on Schizophrenia--impact on the management of schizophrenia.

Authors:  Wolfgang Wölwer; Anja Baumann; Andreas Bechdolf; Gerhard Buchkremer; Heinz Häfner; Birgit Janssen; Joachim Klosterkötter; Wolfgang Maier; Hans-Jürgen Möller; Stephan Ruhrmann; Wolfgang Gaebel
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

Review 8.  The nature of relapse in schizophrenia.

Authors:  Robin Emsley; Bonginkosi Chiliza; Laila Asmal; Brian H Harvey
Journal:  BMC Psychiatry       Date:  2013-02-08       Impact factor: 3.630

Review 9.  Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life.

Authors:  Cristiana Montemagni; Tiziana Frieri; Paola Rocca
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-19       Impact factor: 2.570

Review 10.  Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia.

Authors:  Claudio Brasso; Silvio Bellino; Paola Bozzatello; Cristiana Montemagni; Paola Rocca
Journal:  Neuropsychiatr Dis Treat       Date:  2017-11-07       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.